
Burnout syndrome: when the pressure at work makes us sick
29 May 2019
Family and Community Medicine Excellent Resident Award
30 May 2019Multiple Sclerosis (MS) is the most common chronic neurological disease in young people in Europe and the US, affecting women to a greater extent and occupying first place among the neurological disorders that cause disability in young adults.
The Lozano Blesa Clinical Hospital has organized the I Multiple Sclerosis Conference for patients and families In collaboration with the IIS Aragón and Salud Aragón, it has had the support of the pharmaceutical company Novartis and the Aragonese Association of Multiple Sclerosis (FADEMA). The event served to offer the latest advances from the IIS-Aragón research group with a multidisciplinary approach to this neurological disease whose incidence ranges between 1 and 40 new patients per year per 100.000 inhabitants. In the IIS Aragón research group LAGENBIO (TERAGEN AND REGENERAGEN) are Dr. Cristina Iñiguez, head of the Neurology service at the University Clinical Hospital, and Dr. Moisés Garcés, neurologist at the University Clinical Hospital and expert in Multiple Sclerosis.
Multiple Sclerosis is the most common inflammatory disease that damages the covering of nerve fibers in the central nervous system (brain and spinal cord). The lesion that is characterized in this disease is the demyelination plaque or areas of inflammation with damaged myelin.
Multiple sclerosis is the most common chronic neurological disease in young people in Europe and the US and in young adults it occupies first place among the neurological disorders that cause disability. The incidence ranges between 1 and 40 new patients per year per 100.000 inhabitants. In Spain there are currently figures of 150 patients per 100.000 and it is estimated that they will increase. It mainly affects people between the ages of 18 and 40. And women suffer from them in a higher proportion than men, almost triple.
During the day, some medical aspects of multiple sclerosis were analyzed, such as the importance of the diagnosis and the symptoms that should be reported to the neurologist, and the working groups that exist in Aragon were presented, characterized by their unity and pioneers in putting into practice. early treatment for patients. “Aragón has a work group in the Health system that we can feel proud of, since it is allowing us earlier treatments with drugs for this disease.”, emphasizes Cristina Iñiguez Martínez, head of the neurology service at the University Clinical Hospital and researcher at the IIS-Aragón.
Likewise, experiences have been shared from the point of view of people who suffer from Multiple Sclerosis, and in this sense representatives of FADEMA have highlighted patient education to modify those environmental factors or personal habits that can be beneficial for the patient, as well as therapies based on multiple disciplines such as rehabilitation.
Other aspects that have been highlighted during the day have been the explanation of the new medicine “ocrelizumab” which is the first that has been authorized for patients with primary progressive multiple sclerosis, clearing up doubts about its use.
On the other hand, important issues such as fertility and reproduction in patients with multiple sclerosis have been addressed.